Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.
ARNI
Effectiveness
Heart failure
Heart failure with mildly reduced ejection fraction
Heart failure with reduced ejection fraction
Real-world
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
07
07
2022
accepted:
22
09
2022
pubmed:
29
11
2022
medline:
21
1
2023
entrez:
28
11
2022
Statut:
ppublish
Résumé
Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) with a class-1 guideline recommendation. We assessed the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) on all-cause and cardiovascular (CV)-related mortality and hospitalizations in heart failure (HF) with reduced or mildly reduced ejection fraction (EF). Patient-level clinical, laboratory, drug dispensation, hospitalization, and mortality data were derived from the Swedish Heart Failure Registry (SwedeHF) and interlinked databases (1 April 2016-31 December 2020). Eligible ARNI:ACEi/ARB patients (n = 7275:24,604) had a left ventricular EF < 50%. Mortality and hospitalizations with ARNI (≤ 3 months pre-/post-1 April 2016 index [SwedeHF]; n = 1506) versus ACEi/ARB (≤ 3 months post-index; n = 17,108) were assessed using propensity score matching (1:1 ratio) with clinical variables, and sensitivity analysis (1:2/1:3 with, and 1:2 without clinical variables). ARNI induced a 23% reduction in all-cause mortality versus ACEi/ARB (1:1 hazard ratio [HR; 95% confidence interval (CI)]: 0.77 [0.63-0.95], p = 0.013), and a non-significant 23% relative risk reduction in CV-related mortality (0.77 [0.54-1.09], p = 0.13), but no difference in all-cause or CV-related hospitalization (1.02 [0.91-1.13]; p = 0.76; 1.01 [0.91-1.15]; p = 0.84, respectively). Sensitivity analyses confirmed all-cause mortality was reduced for ARNI versus ACEi/ARB (HR 0.90 [95% CI 0.82-0.99], p = 0.026), but not CV-related mortality (HR 1.04 [95% CI 0.89-1.22], p = 0.63). In this nationwide real-world study including a population of patients with HF with reduced or mildly reduced EF, ARNI as part of guideline-led Swedish clinical practice was associated with a statistically significant relative risk reduction in all-cause mortality compared with ACEi/ARB.
Identifiants
pubmed: 36443599
doi: 10.1007/s00392-022-02124-w
pii: 10.1007/s00392-022-02124-w
pmc: PMC9849288
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Angiotensin Receptor Antagonists
0
Antihypertensive Agents
0
Drug Combinations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
167-174Informations de copyright
© 2022. The Author(s).
Références
Int J Cardiol. 2021 Mar 15;327:138-145
pubmed: 33301829
ESC Heart Fail. 2020 Dec;7(6):3633-3643
pubmed: 32881399
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Int J Cardiol. 2021 May 15;331:164-171
pubmed: 33545266
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
JACC Heart Fail. 2020 Jan;8(1):43-54
pubmed: 31838035
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
N Engl J Med. 2017 Aug 3;377(5):465-475
pubmed: 28767357
Ups J Med Sci. 2019 Jan;124(1):65-69
pubmed: 30092697
Curr Heart Fail Rep. 2017 Apr;14(2):59-70
pubmed: 28247180
Circulation. 2020 Feb 4;141(5):352-361
pubmed: 31736342
ESC Heart Fail. 2022 Dec;9(6):3737-3750
pubmed: 35921043